Arvinas Inc., Sutro Biopharma Inc. and Urovant Sciences Ltd. became the latest biopharmas to head to Nasdaq, pricing their IPOs to raise a combined $345 million, but – like Entasis Therapeutics Inc. a day earlier – not all enjoyed a warm welcome on their public debut.